Currently, small-sample retrospective analyses and case reports have shown that LCNEC patients have higher levels of PD-L1 expression than other neuroendocrine tumours (especially SCLC) do (5), which suggests that immunotherapy may be effective for some LCNEC patients. This evidence concerns the gene CD274 and large cell neuroendocrine carcinoma.